
Consensus
The community is narrowly leaning bullish on Injective at 52%, based on 5 forecasts. Forecasters are in moderate agreement.
Resolves YES if Injective's price 12 months out is above its baseline price.
Share your read on this question — the best forecasters show their work.
See the whole inj discussion →